Zentalis Pharmaceuticals, Inc.
No SEC Form 4 filings for $ZNTL in the last 30 days.
See all $ZNTL insider activity →Zentalis Pharmaceuticals (ZNTL) reported interim overall survival data from the DENALI Part 1b trial in platinum-resistant ovarian cancer. The data suggests Cyclin E1 as a predictive biomarker and shows favorable survival rates compared to historical chemotherapy in Cyclin E1-positive patients.
Zentalis Pharmaceuticals (ZNTL) reported interim data for its ovarian cancer drug azenosertib, showing median overall survival of 15.8 months in Cyclin E1-positive patients vs. 7.5 months in negative patients. The data will be presented at ESMO Congress 2026. The company is advancing Phase 3 trials for azenosertib in this biomarker-selected population.
Zentalis Pharmaceuticals (ZNTL) stock rose 4.4% in pre-market trading after Leerink Partners upgraded it to Outperform with an $8 price target, up from Market Perform and $4. The firm cited reduced risk for azenosertib, its lead oncology drug, ahead of key clinical data presentations at the ESMO Congress. The broader analyst consensus price target is $6.75. The stock trades within its 52-week range of $1.21 to $6.95.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ZNTL (Zentalis Pharmaceuticals, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ZNTL coverage spans corporate actions, financial news and earnings.
Positive interim OS data may boost investor confidence in Zentalis and its azenosertib program.
Positive survival data in the biomarker‑positive subgroup may boost investor confidence in Zentalis' lead candidate.
Upgrade and upcoming ESMO data suggest upside potential.
Significant insider buying suggests confidence in Zentalis and may support the stock price.
The dilution from a below-market priced equity raise is the immediate driver of downside risk for ZNTL shares.
AlphAI scores every news story that mentions ZNTL with an AI model for sentiment and relevance, and aggregates insider trades from Zentalis Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zentalis Pharmaceuticals (ZNTL) reported interim overall survival data from the DENALI Part 1b trial in platinum-resistant ovarian cancer. The data suggests Cyclin E1 as a predictive biomarker and shows favorable survival rates compared to historical chemotherapy in Cyclin E1-positive patients.
2 min readZentalis Pharmaceuticals (ZNTL) reported interim data for its ovarian cancer drug azenosertib, showing median overall survival of 15.8 months in Cyclin E1-positive patients vs. 7.5 months in negative patients. The data will be presented at ESMO Congress 2026. The company is advancing Phase 3 trials for azenosertib in this biomarker-selected population.
2 min readZentalis Pharmaceuticals (ZNTL) stock rose 4.4% in pre-market trading after Leerink Partners upgraded it to Outperform with an $8 price target, up from Market Perform and $4. The firm cited reduced risk for azenosertib, its lead oncology drug, ahead of key clinical data presentations at the ESMO Congress. The broader analyst consensus price target is $6.75. The stock trades within its 52-week range of $1.21 to $6.95.
1 min readWALTERS GROUP purchased 4,335,000 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) at $3.50 ($15.17M total) on 2026-08-14. Filed jointly with WALTERS WILLIAM THURMAN (10% owner) and WALTERS SUSAN BERKLEY (10% owner).
1 min readZentalis Pharmaceuticals shares fell about 15% in pre-open trading after the company announced and priced a large underwritten public offering. The deal issues 23 million shares at $3.50 each, with an option for up to 3.45 million more. Gross proceeds are about $80.5 million to fund trials and research for azenosertib.
3 min readZentalis Pharmaceuticals (NASDAQ:ZNTL) shares fell about 6.5% in after-hours after it announced an underwritten public offering of common stock and pre-funded warrants. The company plans to use net proceeds plus existing cash for clinical trials, regulatory filings, manufacturing, and general corporate purposes. Joint bookrunners include TD Cowen, Guggenheim, and Oppenheimer.
4 min readZentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates • Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 • Enrollment completed in Part 2a and 2b of the DENALI trial;
6 min readManpowerGroup reported upbeat Q2 results. Adjusted earnings were 99 cents per share, above analysts’ 95 cents estimate. Revenue increased 8% year over year to $4.86 billion, or 6% in constant currency, versus $4.72 billion expected. ManpowerGroup shares rose 5.8% to $54.63 on Friday.
2 min readZentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zntl-20260616 0001725160 FALSE 0001725160 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Dat
3 min readZentalis Pharmaceuticals (Nasdaq: ZNTL) said its Compensation Committee granted non-qualified stock options to two newly hired employees on June 1, 2026, totaling 191,000 shares under Nasdaq Listing Rule 5635(c)(4). Options have a $3.98 exercise price, a 10-year term, and 4-year vesting (25% at year one, then monthly over three years), subject to continued service.
2 min read
